Piper Sandler reiterates Doximity stock rating on AI opportunity By Investing.com

Doximity reported Q4 revenue of $145.4 million, up 5.1% year over year and ahead of estimates, with adjusted EBITDA of $65.8 million also beating expectations. However, fiscal 2027 revenue guidance of $664 million to $676 million implies only 3% to 5% growth, below the Street’s $699 million estimate, prompting multiple analyst downgrades and price-target cuts. Piper Sandler kept an Overweight rating and $42 target, citing AI-driven search monetization potential and sponsored content upside.

Analysis

DOCS is now a classic “show-me” stock where the debate has shifted from quality to durability. The near-term problem is not the quarter itself; it’s that guidance compresses the visible growth path just as management is spending into AI, which creates a multiple headwind because investors are paying for a monetization inflection that may not arrive until late FY27 or FY28. In that setup, any incremental execution miss tends to hit the stock harder than the underlying fundamentals would justify.

The second-order issue is competitive positioning around paid search and sponsored content. If Doximity can successfully monetize clinician intent, it becomes less of a pure workflow/engagement business and more of a performance-adjacent advertising platform, which is structurally higher value—but only if the product works and conversion data is strong enough to protect ROI. That makes the new CFO transition relevant: this is a capital-allocation and measurement story now, and investors will want evidence that AI spend is translating into unit economics rather than just top-line experimentation.

Consensus may be underappreciating how much of the downside is already embedded after the drawdown, but the stock can stay cheap if growth inflects only modestly. The cleaner contrarian setup is not to buy the revenue guide; it is to buy the optionality on monetization while hedging the execution gap. In the next 1-2 quarters, the key catalyst is whether sponsored content in Ask shows enough early traction to lift ad load without impairing user engagement; if it does, the market will likely rerate FY28 more than FY27.

For EVR, the read-through is minor but slightly negative on the M&A calendar: a more cautious healthcare software tape can dampen smaller-cap advisory sentiment around tech-enabled services. That is not a direct earnings risk, but it can shave near-term multiple appetite for transaction-heavy growth names if investors de-risk across software-adjacent media and advisory exposure.

Key Decisions for Investors

• Short DOCS into any pre-open strength or post-earnings relief rally; target 4-8 weeks, with a stop above the prior breakdown level, because the market is likely to fade until FY27/Ask monetization evidence is visible.
• For patient capital, initiate a small starter long DOCS only on a further 10-15% drawdown or after one quarter of sponsored-content traction; treat as a 6-12 month optionality trade, not a core growth position.
• Use a DOCS call spread calendar or diagonal: long longer-dated upside optionality, short near-dated premium, to express belief in FY28 monetization while paying for the execution risk over the next 1-2 quarters.
• Avoid adding to EVR until healthcare/tech issuance sentiment stabilizes; if anything, use it as a relative short against stronger secular M&A beneficiaries where guidance risk is lower.